January 29, 2015
1 min read

Dapagliflozin combination improved glycemic control, reduced body weight in type 2 diabetes

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Dapagliflozin as an add-on to metformin plus sulfonylurea improved glycemic control and reduced body weight in patients with type 2 diabetes, according to recent study findings published in Diabetes Care.

Stephan Matthaei, MD, of the Diabetes-Zentrum Quakenbrück in Germany, and colleagues evaluated participants (mean age, 61 years) with an HbA1c of 7% to 10.5% receiving sulfonylurea and metformin who were assigned to receive dapagliflozin (Farxiga, Bristol-Myers Squibb and AstraZeneca) 10 mg/day (n=109) or placebo (n=109) to determine the effect on inadequate glycemic control.

Compared with the placebo group, the dapagliflozin group had significantly reduced HbA1c levels from baseline to 24 weeks (P<.0001). At week 24, more patients on dapagliflozin achieved a therapeutic glycemic response compared with those receiving placebo (P<.0001). Fasting plasma glucose and body weight also decreased more throughout the study period among the dapagliflozin group compared with placebo (both P<.0001).

From baseline to week 8, patients assigned dapagliflozin had a significantly greater reduction in seated systolic blood pressure compared with those assigned placebo (P=.025).

Ten placebo patients required rescue for lack of glycemic control at week 24 compared with zero dapagliflozin patients.

Placebo-subtracted increases were seen in total (P=.0091), LDL (P=.003) and HDL cholesterol (P=.0172) among patients in the placebo group; no differences were observed in LDL-HDL cholesterol ratio (P=.2008) or triglyceride levels (P=.1755). No change was seen in serum levels of C-peptide in either group.

The placebo (51.4%) and dapagliflozin (48.6%) groups had similar rates of adverse events. Compared with the placebo group, the dapagliflozin group experienced more events of hypoglycemia (P=.024) and genital infections (P=.029).

“The results presented here indicate that triple combination therapy that includes dapagliflozin 10 mg/day with metformin and sulfonylurea is a suitable treatment option for patients with inadequate glycemic control on metformin and a sulfonylurea, with the added benefits of weight loss and BP reduction,” the researchers wrote. “Consistent with other [sodium-glucose cotransporter 2] inhibitors, dapagliflozin was associated with an increase in frequency of genital infections and increase in total, LDL and HDL cholesterol that may necessitate additional lipid management.”

Disclosure: The study was sponsored by Bristol-Myers Squibb and AstraZeneca. Matthaei reports various financial ties with Abbott, AstraZeneca, Bayer, Bristol-Myers Squibb, Boehringer Ingelheim, Janssen, Lilly, Merck, Novartis, Novo Nordisk, Roche and Sanofi.